Current and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexate

Thanyanan Reungwetwattana, Sylvia Jaramillo, Julian R. Molina

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Peripheral T-cell lymphomas (PTCL) represent about 12%-15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile and activity, Pralatrexate has become a major compound for patients with refractory PTCL.

Original languageEnglish (US)
Pages (from-to)125-135
Number of pages11
JournalClinical Medicine Insights: Therapeutics
StatePublished - 2011


  • Pralatrexate
  • Review
  • T-cell lymphoma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science


Dive into the research topics of 'Current and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexate'. Together they form a unique fingerprint.

Cite this